Exagen (XGN) Competitors $9.56 -0.09 (-0.93%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$9.56 0.00 (0.00%) As of 09/19/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XGN vs. CDNA, FLGT, CSTL, INNV, PSNL, SBC, AUNA, AGL, TALK, and EHABShould you be buying Exagen stock or one of its competitors? The main competitors of Exagen include CareDx (CDNA), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), InnovAge (INNV), Personalis (PSNL), SBC Medical Group (SBC), Auna (AUNA), Agilon Health (AGL), Talkspace (TALK), and Enhabit (EHAB). These companies are all part of the "healthcare" industry. Exagen vs. Its Competitors CareDx Fulgent Genetics Castle Biosciences InnovAge Personalis SBC Medical Group Auna Agilon Health Talkspace Enhabit Exagen (NASDAQ:XGN) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Which has more volatility & risk, XGN or CDNA? Exagen has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, CareDx has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Do insiders and institutionals have more ownership in XGN or CDNA? 75.3% of Exagen shares are owned by institutional investors. 12.6% of Exagen shares are owned by company insiders. Comparatively, 4.4% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation and earnings, XGN or CDNA? CareDx has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExagen$58.86M3.57-$15.11M-$0.89-10.74CareDx$333.79M2.33$52.55M$1.0214.30 Is XGN or CDNA more profitable? CareDx has a net margin of 17.97% compared to Exagen's net margin of -28.85%. CareDx's return on equity of 18.03% beat Exagen's return on equity.Company Net Margins Return on Equity Return on Assets Exagen-28.85% -130.38% -34.69% CareDx 17.97%18.03%12.88% Do analysts rate XGN or CDNA? Exagen presently has a consensus target price of $12.00, indicating a potential upside of 25.52%. CareDx has a consensus target price of $25.50, indicating a potential upside of 74.78%. Given CareDx's higher possible upside, analysts plainly believe CareDx is more favorable than Exagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exagen 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00CareDx 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Does the media prefer XGN or CDNA? In the previous week, CareDx had 3 more articles in the media than Exagen. MarketBeat recorded 5 mentions for CareDx and 2 mentions for Exagen. Exagen's average media sentiment score of 1.02 beat CareDx's score of 0.86 indicating that Exagen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CareDx 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCareDx beats Exagen on 10 of the 16 factors compared between the two stocks. Get Exagen News Delivered to You Automatically Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XGN vs. The Competition Export to ExcelMetricExagenMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$210.36M$10.74B$5.79B$10.40BDividend YieldN/A1.88%5.63%4.60%P/E Ratio-10.7421.6480.5826.78Price / Sales3.5731.96534.22123.54Price / CashN/A24.5037.9961.55Price / Book17.703.4215.776.40Net Income-$15.11M$210.63M$3.30B$271.80M7 Day Performance-1.85%-0.02%5.36%3.48%1 Month Performance-2.85%1.47%8.10%9.90%1 Year Performance222.97%-9.87%81.36%28.44% Exagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XGNExagen4.5539 of 5 stars$9.56-0.9%$12.00+25.5%+235.4%$210.36M$58.86M-10.74220Positive NewsCDNACareDx4.1005 of 5 stars$14.02+3.6%$25.50+81.9%-51.2%$720.16M$333.79M13.75740FLGTFulgent Genetics3.8559 of 5 stars$21.98+0.5%$25.33+15.3%-2.5%$669.73M$283.47M-13.241,313Positive NewsCSTLCastle Biosciences2.678 of 5 stars$21.62+0.9%$37.00+71.1%-20.0%$621.35M$346.27M-61.77540INNVInnovAge0.8927 of 5 stars$4.98+9.5%$5.00+0.4%-24.1%$617.15M$853.70M-21.652,440News CoverageAnalyst ForecastHigh Trading VolumePSNLPersonalis3.8128 of 5 stars$5.93+1.4%$7.42+25.1%+2.9%$518.76M$80.32M-4.63400News CoverageAnalyst UpgradeSBCSBC Medical Group1.39 of 5 stars$4.52+0.9%N/AN/A$469.54M$188.19M14.13N/AAnalyst UpgradeGap UpAUNAAuna3.6802 of 5 stars$6.35+0.3%$10.70+68.5%-14.8%$468.50M$4.33B7.2114,842AGLAgilon Health2.1286 of 5 stars$1.12+4.2%$3.07+175.5%-69.8%$443.43M$6.06B-1.451,076TALKTalkspace3.9322 of 5 stars$2.56flat$4.50+75.8%+21.9%$428.72M$202.61M128.06500Positive NewsEHABEnhabit1.9804 of 5 stars$7.71-2.1%$8.67+12.5%-0.6%$398.93M$1.03B-2.8910,700 Related Companies and Tools Related Companies CDNA Alternatives FLGT Alternatives CSTL Alternatives INNV Alternatives PSNL Alternatives SBC Alternatives AUNA Alternatives AGL Alternatives TALK Alternatives EHAB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XGN) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
